제네릭 무균 주사제 시장 : 약제 유형별, 치료 용도별, 유통 채널별, 지역별
Generic Sterile Injectables Market, by Drug Type, by Therapeutic Application, by Distribution Channel and by Region
상품코드
:
1705738
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계의 제네릭 무균 주사제 시장은 2025년에는 464억 3,000만 달러에 달하고, 2032년에는 933억 9,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지의 연평균 성장률(CAGR)은 10.5%를 나타낼 것으로 전망됩니다.
| 보고 범위 |
보고서 세부정보 |
| 기준 연도 |
2024년 |
시장 규모(2025년) |
464억 3,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간 : 2025-2032년 CAGR : |
10.50% |
가치 예측(2032년) |
933억 9,000만 달러 |
그림. 제네릭 무균 주사제 시장 점유율(%), 지역별(2025년)
제네릭 무균 주사제는 미국 FDA가 승인한 생물 제제이며 건강 관리 산업의 광범위한 분야에서 많은 질병과 장애를 치료하는 데 사용됩니다. 주사제는 항상 수요가 많으며 세계 병원 및 클리닉의 대부분에서 사용되고 있습니다.
제네릭 무균 주사제 시장은 무균 주사제가 다양한 질병이나 병리에 적용됨에 따라 예측 가능한 장래에 안정된 견인력을 얻을 것으로 기대됩니다.
시장 역학
시장 기업은 제네릭 무균 주사제의 신제품을 출시하기 위해 노력하고 있으며, 이는 예측 기간에 걸쳐 세계 제네릭 무균 주사제의 성장을 증가시킬 것으로 예측됩니다. 예를 들어, 2017년 6월 박스터 인터내셔널은 일반적으로 처방되는 세 가지 제형(300mg/ 50mL, 600mg/ 50mL, 900mg/ 50mL)의 식염수 클린다마이신 주사를 즉시 사용할 수 있도록 미국 FDA의 승인을 받아 상업적으로 출시했다고 발표했습니다. 클린다마이신은 페니실린이 환자에게 부적절한 경우에 민감한 혐기성 세균이나 연쇄상 구균, 폐렴구균, 포도상구균의 균주에 기인하는 심각한 감염증에 널리 처방되는 항생제입니다.
주요 기업은 파트너십과 같은 무기적 활동에 주력하고 있으며, 이는 예측 기간 동안 세계의 제네릭 무균 주사제 시장 성장을 증가시킬 것으로 예측됩니다. 예를 들어, 2017년 노바티스의 제네릭 사업부인 Sandoz는 시설 개발 및 현대화를 위해 3,354만 달러 이상을 투자하여 슬로베니아에 항생제 생산 시설을 확장했습니다.
이 회사는 세계적인 존재를 확대하고 국제적인 사업 기회를 향상시키기 위해 인수와 같은 무기 성장 전략을 채택하는 데 주력하고 있습니다.
본 조사의 주요 특징
- 본 보고서는 세계의 제네릭 무균 주사제 시장을 상세하게 분석했으며, 2024년을 기준 연도로 한 예측 기간(2025-2032년) 시장 규모를 제공합니다.
- 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
- 또, 시장 성장 촉진요인, 성장 억제요인, 기회, 신제품의 출시나 승인, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
- 기업 개요, 재무 실적, 제품 포트폴리오, 지리적 존재, 유통 전략, 주요 발전과 전략, 장래 계획 등의 파라미터에 근거해, 세계의 제네릭 무균 주사제 시장 주요 기업을 프로파일하고 있습니다.
- 이 보고서로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 발매, 기술 향상, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
- 세계의 제네릭 무균 주사제 시장 보고서는 투자자, 공급업체, 제조업체, 유통 업체, 신규 참가자, 재무 분석가 등이 업계의 다양한 이해 관계자를 대상으로 합니다.
- 이해관계자는 세계의 제네릭 무균 주사제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해, 의사 결정을 용이하게 할 수 있습니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 개요
- 보고서 설명
- 주요 요약
- 일관된 기회 맵(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 규제 시나리오
- PEST 분석
- 최근 제품 출시/승인
- 역학
- 합병과 인수
제4장 세계의 제네릭 무균 주사제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- 공급망에 미치는 영향
- 연구개발에 미치는 영향
- 정부의 대처
제5장 세계의 제네릭 무균 주사제 시장, 약제 유형별(2020-2032년)
- 단일클론항체
- 사이토카인
- 인슐린
- 펩티드 호르몬
- 백신
- 면역글로불린
- 혈액 인자
- 항생제
- 기타
제6장 세계의 제네릭 무균 주사제 시장, 치료 용도별(2020-2032년)
- 암
- 대사성 질환
- 심혈관 질환
- 중추 신경계 질환
- 감염성 질환
- 근골격계 장애
- 기타
제7장 세계의 제네릭 무균 주사제 시장, 유통 채널별(2020-2032년)
제8장 세계의 제네릭 무균 주사제 시장, 지역별(2020-2032년)
- 북미
- 라틴아메리카
- 유럽
- 아시아태평양
- 중동
- 아프리카
제9장 경쟁 구도
- 기업 프로파일
- Baxter International Inc.
- AstraZeneca plc
- Merck &Co., Inc.
- Pfizer Inc.
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan NV
- Sun Pharmaceutical Industries Ltd.
제10장 분석가 추천
제11장 섹션
KTH
영문 목차
Global Generic Sterile Injectables Market is estimated to be valued at USD 46.43 Bn in 2025 and is expected to reach USD 93.39 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.5% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 46.43 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
10.50% |
2032 Value Projection: |
USD 93.39 Bn |
Figure. Generic Sterile Injectables Market Share (%), By Region 2025
The generic sterile injectable are U.S. FDA approved biologics that are used for the treatment of many diseases and disorders in the vast arena of the healthcare industry. The generic sterile injectable are very inexpensive as compared to that of their branded counterparts of these drugs and performs equally well. Thus, these Injectables are heavily in demand all the time and are used in majority of hospitals and clinics across the globe. However, due to the stringent FDA regulations for the production of these injectable, the rigorous demand satisfaction of these injectable has always been a constant challenge for the key players in the global generic sterile injectable market.
The generic sterile injectable market is expected to gain steady traction in the foreseeable future as the sterile injectable products find its application across a wide number of diseases and medical condition. Manufacturers are focused on increasing the production of generic sterile injectable to meet the rising demands without compromising on the quality of the injectable.
Market Dynamics
Market players are engaged in launching new products for generic sterile injectables, this is expected to increase the growth of the global generic sterile injectables, over the forecast period. For instance, in June 2017, Baxter International Inc. announced the U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations (300mg/50mL, 600mg/50mL, and 900mg/50mL). Clindamycin is a widely prescribed antibiotic for serious infections which is caused by susceptible anaerobic bacteria and strains of streptococci, pneumococci and staphylococci, when penicillin is inappropriate for a patient.
Key players are focusing on inorganic activities such as partnerships, this is expected to increase the growth of the global generic sterile injectables market, over the forecast period. For instance, in 2017, Novartis' generic arm Sandoz expanded its antibiotic facility in Slovenia, with an investment of over US$ 33.54 million aimed at the development and modernization of facilities. The first production lines started in 2020, after which new lines will be gradually phased in by 2024.
The company is focused on adopting inorganic growth strategies such as acquisitions to expand its global presence and improve international commercial opportunities. For instance, in August 2016, Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan's generics business. Allergan plc.is an American, Irish-domiciled pharmaceutical company.
Key features of the study:
- This report provides an in-depth analysis of the global generic sterile injectables market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global generic sterile injectables market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy's Laboratory, Mylan N.V., and Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global generic sterile injectables market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global generic sterile injectables market
Detailed Segmentation:
- Global Generic Sterile Injectables Market, By Drug Type:
- Monoclonal Antibodies
- Cytokines
- Insulin
- Peptide Hormones
- Vaccines
- Immunoglobulins
- Blood Factors
- Antibiotics
- Others
- Global Generic Sterile Injectables Market, By Therapeutic Application:
- Cancer
- Metabolic Diseases
- Cardiovascular Diseases
- Central Nervous System Disease
- Infectious Disorders
- Musculoskeletal Disorders
- Others
- Global Generic Sterile Injectables Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Generic Sterile Injectables Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles
- Baxter International Inc.
- AstraZeneca plc
- Merck & Co., Inc.
- Pfizer Inc.
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- PEST Analysis
- Recent Product Launch/Approval
- Epidemiology
- Mergers and Acquisitions
4. Global Generic Sterile Injectables Market - Impact of Coronavirus (Covid-19) Pandemic
- Impact on Supply Chain
- Impact on Research and Development
- Government Initiatives
5. Global Generic Sterile Injectables Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Peptide Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Blood Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
6. Global Generic Sterile Injectables Market, By Therapeutic Application, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Metabolic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Central Nervous System Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Infectious Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Musculoskeletal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
7. Global Generic Sterile Injectables Market, By Distribution Channel, 2020 - 2032 (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Bn)
8. Global Generic Sterile Injectables Market, By Region, 2020 - 2032 (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2020 - 2032
- Regional Trends
- North America
- Market Size and Forecast, By Drug Type, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Country, 2020 - 2032 (US$ Bn)
- Latin America
- Market Size and Forecast, By Drug Type, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Country, 2020 - 2032 (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Country, 2020 - 2032 (US$ Bn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Country, 2020 - 2032 (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Type, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Country, 2020 - 2032 (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (US$ Bn)
- Market Size and Forecast, By Country, 2020 - 2032 (US$ Bn)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Company Profiles
- Baxter International Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca plc
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Merck & Co., Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Fresenius Kabi
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novartis International AG
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceuticals
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Hikma Pharmaceuticals
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Reddy's Laboratory
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Mylan N.V.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
10. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. Section
- References
- Research Methodology
- About Us and Sales Contact
관련자료
